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ABSTRACT
Introduction: Arthroscopic partial meniscectomy
(APM) to treat degenerative meniscus injury is the
most common orthopaedic procedure. However, valid
evidence of the efficacy of APM is lacking. Controlling
for the placebo effect of any medical intervention is
important, but seems particularly pertinent for the
assessment of APM, as the symptoms commonly
attributed to a degenerative meniscal injury (medial
joint line symptoms and perceived disability) are
subjective and display considerable fluctuation, and
accordingly difficult to gauge objectively.
Methods and analysis: A multicentre, parallel
randomised, placebo surgery controlled trial is being
carried out to assess the efficacy of APM for patients
from 35 to 65 years of age with a degenerative
meniscus injury. Patients with degenerative medial
meniscus tear and medial joint line symptoms, without
clinical or radiographic osteoarthritis of the index knee,
were enrolled and then randomly assigned (1 : 1) to
either APM or diagnostic arthroscopy (placebo
surgery). Patients are followed up for 12 months.
According to the prior power calculation, 140 patients
were randomised. The two randomised patient groups
will be compared at 12 months with intention-to-treat
analysis. To safeguard against bias, patients, healthcare
providers, data collectors, data analysts, outcome
adjudicators and the researchers interpreting the
findings will be blind to the patients’ interventions
(APM/placebo). Primary outcomes are Lysholm knee
score (a generic knee instrument), knee pain (using a
numerical rating scale), and WOMET score (a disease-
specific, health-related quality of life index). The
secondary outcome is 15D (a generic quality of life
instrument). Further, in one of the five centres
recruiting patients for the randomised controlled trial
(RCT), all patients scheduled for knee arthroscopy due
to a degenerative meniscus injury are prospectively
followed up using the same protocol as in the RCT to
provide an external validation cohort. In this article, we
present and discuss our study design, focusing
particularly on the internal and external validity of our




▪ This article describes a protocol for a multicen-
tre, blinded, randomised placebo surgery con-
trolled trial, using a parallel two-arm design to
investigate the efficacy of arthroscopic partial
meniscectomy (APM) in patients with degenera-
tive meniscus injury.
▪ We will also describe a novel ‘RCT
within-a-cohort’ study design that aims to
improve the generalisability of randomised con-
trolled trials (RCTs) in general.
Key messages
▪ The immediate goal of this trial is to provide evi-
dence on the ‘true’ efficacy of APM, the most
common orthopaedic procedure.
▪ Controlling for the placebo effect is a critical
aspect of experimental design in any clinical
research, particularly when assessing the
success of treatment of degenerative orthopaedic
complaints. Optimally, it requires the use of
placebo surgery.
▪ The ‘RCT within-a-cohort’ study design will mark
the first undertaking of an orthopaedic trial to
address the inevitable trade-off between internal
and external validity. The rigorous design, organ-
isation and execution of this trial aim to set a
new standard for future clinical trials in
orthopaedics.
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Ethics and dissemination: The protocol has been approved by the
institutional review board of the Pirkanmaa Hospital District and the
trial has been duly registered at ClinicalTrials.gov. The findings of
this study will be disseminated widely through peer-reviewed
publications and conference presentations.
Trial registration: ClinicalTrials.gov, number NCT00549172.
INTRODUCTION
Middle-aged men and women with knee pain attributed
to degenerative knee disease (a degenerative meniscal
injury accompanied by varying degrees of knee osteo-
arthritis (OA)) constitute the largest group of patients
referred to orthopaedic surgeons.1–4 The prevailing
understanding regarding the aetiology and treatment of
degenerative knee disease is quite mechanical in nature:
knee pain perceived by the patient is attributed to a
degenerative meniscus injury or chondral derangement.
The symptoms related to degenerative meniscus injury
are commonly chronic and ﬂuctuating in nature.
However, somewhat paradoxically, a recent population-
based MRI study showed degenerative meniscal tears to
be highly prevalent in middle-aged and elderly adults
and they seem to be asymptomatic in the majority of
individuals.5 6 The current treatment strategy of early
degenerative knee disease includes rest, oral non-
steroidal anti-inﬂammatory drugs, glucocorticosteroid
injections, physiotherapy and ultimately arthroscopic
removal of mechanical derangement (arthroscopic
partial meniscectomy (APM) or debridement).7 In the
USA alone, one million knee arthroscopies are per-
formed annually to treat degenerative knee disease,
making arthroscopic surgery of the knee by far the most
common orthopaedic procedure.8 9 Many patients
report improvement (reduced knee pain, better func-
tion and improved quality of life) after this kind of
surgery.10–13 However, similar results have also been
obtained with conservative treatment in randomised,
non-placebo-controlled trials.14–16 To date, there is a
dire lack of high-quality evidence (from randomised
controlled trials, RCT) on the efﬁcacy of APM.17 This
issue cannot be addressed simply by evaluating the out-
comes of patients who have undergone surgery, as the
role of the underlying degenerative process and the sur-
gical procedure cannot be unravelled in such a study
design.18 19
It is widely agreed that controlling for the placebo
effect is a critical aspect of experimental design in any
clinical research.20 21 A comprehensive meta-analysis of
the ‘placebo effect’ indicated that subjective outcomes
may be attributable to ‘placebo effects’ or bias.20 As sub-
jective measures or patient-reported outcomes—such as
the amount of pain or perceived disability—are often
used and also widely recommended as primary out-
comes in assessing the success of treatment of degenera-
tive orthopaedic complaints,22 23 the issue of the
possible ‘placebo effects’ of surgery is of utmost rele-
vance. This is an obvious argument favouring the use of
sham surgery to control for the imminent bias. Optimal
blinding of both the patient and the physician-
researcher is another clear asset of the sham-surgical
model: patients are biased towards favourable outcomes
after surgical intervention because they want to believe
that they chose the correct option for their care. This
‘leap of faith’ is believed to be greater in surgery than in
medical trials, in which the perceived and real risks of
the intervention may be more subtle, less severe and do
not involve the pain and risks of invasive procedures.24
Equally importantly, sham surgery is ideal for minimis-
ing the investigator-bias through true blinding of the
outcome assessor.25
Although the ﬁrst-ever sham surgery controlled clin-
ical trial was published as early as in 1959,26 there has
been a paucity of placebo surgery controlled trials in
orthopaedics.27 28 Even discussion regarding the use of
the sham surgery model has been limited and generally
condemning or censorious.27 29 30 The essential ques-
tion regarding the ethics of the use of placebo surgery
concerns the dilemma between the provision of the
highest standard of research design (the double-blind,
randomised, placebo-controlled trial) and the highest
standard of ethics (to do no harm to the patient).29
When evaluating the merits of a study protocol, the insti-
tutional review board (IRB) should consider not only
the risks and beneﬁts that may result from the research
but also the possible long-term effects of applying knowl-
edge gained in the research as among the research risks
that fall within the purview of its responsibility.21 27
Dowrick and Bhandari recently proposed that there are
four areas that deserve particular attention when decid-
ing on the appropriateness of a sham surgery controlled
RCT, namely the equipoise, risk minimisation, informed
consent and deception. As our views on the last
three issues are thoroughly expressed in the
ethical annex (box 1), we will focus here on equipoise.
In short, the statement by Dowrick and Bhandari21 that
“In orthopaedics, the reality is that many treatments are
‘known,’ ‘accepted,’ or ‘standard’ but may not yet be
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Our protocol paper will present a detailed ethical analysis of
the use of placebo surgery, a framework that future placebo
surgery controlled trials in orthopaedics are suggested to
follow.
▪ The rationale supporting placebo surgery controlled design
includes demonstrated considerable ‘placebo effect’ in surgical
trials and optimal blinding of both the patient and the
physician-researcher.
▪ The study is limited to degenerative meniscus injury. The def-
inition of the concepts ‘degenerative’ or ‘traumatic’ in the
context of meniscal injuries is arbitrary in nature.
▪ This is a protocol paper; the trial is underway, but has not
been completed.
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‘proven’ in the true sense of the word as it applies to
scientiﬁc research” captures the essence of equipoise
and APM.
RCT is considered the gold standard of research
design in terms of methodological rigour (internal valid-
ity). Ideally, a well-designed RCT should not only have
high internal validity but also preferably high external
validity (generalisability).25 However, realistically, such a
‘wish’ is an obvious paradox, as there is an almost inevit-
able trade-off between internal and external validity. In
essence, the purpose of a true efﬁcacy (or explanatory)
trial is to demonstrate that an intervention can work the-
oretically under optimal conditions (‘best-case scen-
ario’). The patients recruited are thus carefully selected
to obtain as homogeneous a sample as possible and they
are also treated under ideal conditions (eg, by the most
skilled/experienced physicians). An effectiveness (or
pragmatic) trial, in turn, is aimed at testing how an inter-
vention works under usual practice circumstances, and
for this reason has a high external validity, but the
internal validity is usually lower.25 42 43 Relton et al44
recently described a novel ‘cohort multiple randomised
controlled trial’ design, in which the beneﬁts of a large
observational cohort and a pragmatic RCT can be com-
bined. However, this pragmatic design cannot be used
for trials with a placebo comparator (ie, ‘true’ efﬁcacy
design) as the patients may not receive placebo in
routine healthcare.
In this paper, we describe the protocol of our ongoing
placebo surgery controlled trial assessing the efﬁcacy of
APM. To address some of the problems related to both
efﬁcacy and effectiveness RCTs, we also brieﬂy introduce
a novel ‘RCT within-a-cohort design’. This protocol
paper has been written according to the recently pub-
lished SPIRIT guidelines.45 Hopefully, the publication of
this article will make our study objectives and methods
more transparent and consequently improve the even-
tual utility of our study.46
Box 1 Ethical considerations of using placebo surgery control, as outlined by Miller31
I. Is there scientific and clinical value in conducting this study?
Despite being the most common orthopaedic procedure, there exists no randomised, placebo-controlled study on the efficacy (risk-benefit
ratio) of arthroscopic partial meniscectomy (APM). We would like to emphasise that a properly conducted efficacy trial on APM could
provide better evidence-base for this procedure and theoretically eliminate unnecessary procedures or at least provide the field with prognos-
tic factors for good/poor outcome.
II. Is the use of placebo surgery methodologically necessary or desirable to achieve valid results?
Given on the one hand the subjective and somewhat vague nature of the symptoms related to degenerative meniscus injury (fluctuating
course of symptoms that range from one individual to another from spontaneous disappearance of the symptoms to quite dramatic impair-
ment in the quality of life), and on the other, the well-known strong placebo effect of surgical interventions,27 32 we feel confident in stating
that there is indeed no alternative to using placebo surgery as a control.
III–V. Risk–benefit assessment
A basic ethical requirement of clinical research is to minimise risks.33 This does not mean that risks can be reduced to zero or that risks
must be minimal.31 The risks inherent in our placebo surgery procedure are related to spinal anaesthesia and arthroscopy. Spinal anaesthe-
sia does carry a modest risk (mainly of postspinal headache), but similar risks have been considered acceptable for other medical investiga-
tors, such as spinal tap for neurological diseases or when used to carry out muscle biopsies for neurological or orthopaedic study designs
or bronchoscopy.34 As for the risks related to knee arthroscopy per se, the most common are wound infection, deep venous thrombosis
and pulmonary embolism with respective incidences of 0.22%, 0.12% and 0.08%.35 There is naturally also a risk for iatrogenic lesions
(chondral surfaces) inside the knee during the procedure, but given the fact that all surgeons performing the operations in the RCT are
highly skilled with experience of hundreds of previous knee arthroscopies, these are considered negligible. In addition, knee arthroscopy is
commonly used as a diagnostic procedure for patients with knee pain, and accordingly the patients allocated to the placebo surgery arm can
be considered to gain by being assured that no pathology other than a degenerative meniscus injury exists in their knee joint. The other
ethical dilemma regarding our procedure actually lies at the heart of our study design, the potential harms and benefits related to the resec-
tion of the torn meniscus. The existing evidence shows quite convincingly no benefit of knee arthroscopy in the prevention of the degenera-
tive process (knee osteoarthritis (OA)),36–38 and accordingly few would argue that the goal of APM in patients with degenerative meniscus
injury is solely to relieve symptoms. On this note, there is naturally a risk that patients allocated to the sham arm will suffer from the delay
in getting the potentially beneficial procedure, a risk that we have attempted to minimise by allowing patients to request a reassessment of
their symptoms (and potentially cross over to the APM arm) after 6 months of follow-up. It should also be noted that all the risks discussed
above are related to the current treatment strategy of degenerative meniscus injury, the resection of the meniscus and the recent evidence
actually implies that meniscectomy is associated with an increased risk of future knee OA.39 40 Finally, we contend that there are no objective
tools for measuring risk-benefit ratios in research. As Gillett has suggested: ‘an acceptable procedure for the placebo arm of a surgical trial
is one that carries no more risk than the investigation that would be used to diagnosis and treatment’.41 We argue that the relatively minor
risks related to placebo procedure were justifiable to answer the clinically important question of whether arthroscopic surgery is effective in
the treatment of degenerative meniscus injury.
VI. Do the individuals give informed consent?
The ethical issues of the trial will be thoroughly explained and discussed with each recruited patient, both verbally and in writing. The
basic principles laid down in the Declaration of Helsinki will be followed throughout the execution of the trial. Accordingly, each participant
has the right to withdraw from the study at any given moment without having to explain this decision in any way. Finally, the possibility of
being randomised to placebo surgery will be reiterated to each participant before the actual randomisation.
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METHODS AND ANALYSIS
Study design
We are conducting a parallel (1 : 1), multicentre, rando-
mised and placebo surgery controlled superiority trial to
assess the efﬁcacy of APM for patients with a degenera-
tive medial meniscus injury (ﬁgure 1). Patients,
outcome assessors and data analysts (before the ﬁnal
writing of the manuscript) will be unaware of treatment
assignments (triple blind approach).
All patients have been given a written informed
consent form and have been made to realise that on
entering the study they may receive only placebo
surgery, in which case the meniscus tear will be left
untreated. They also know that participation in the study
is entirely voluntary and the decision they make will not
affect their possible future care (in case of refusal). In
addition, every patient has been informed of their right
to withdraw from the trial whenever they desire without
giving the researchers any reason for their decision.
We have enrolled patients at the outpatient clinics of
ﬁve secondary or tertiary hospitals in Finland. The study
was ﬁrst launched at one site, but to improve recruit-
ment after 2 years (and to ensure multicentre design
with its obvious beneﬁts to the generalisability of the
results), the study was expanded to four additional sites.
The sites were selected on the basis of having an estab-
lished practice of knee arthroscopy and also an experi-
enced arthroscopic knee surgeon keen to participate in
the study. All orthopaedic surgeons involved in the
actual interventions of the study are members of the
Finnish Arthroscopy Association and have experience of
more than 1300 (range 1300–2500) knee arthroscopies
with an annual rate of at least 200 (range 200–350) arth-
roscopies. Before the actual launch of the study at the
four additional study centres, the protocol was discussed
in the minutest details to ensure that it would be
adhered to in a similar manner in all ﬁve centres. The
principal clinical investigator and the study coordinator
Figure 1 Flowchart of the efficacy trial: enrolment, assigned intervention and follow-up scheme.
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also visited every centre at least once before the study
was begun at these selected sites. Further, regular meet-
ings have been held biannually among all study
members to ensure that the protocol is carried out as
planned.
Participants
Patients referred to any of the ﬁve orthopaedic surgeons
and complaining of knee pain consistent with a menis-
cus injury were assessed for eligibility. Eligible patients
were 35–65 years of age with persisting symptoms (more
than 3 months) consistent with a degenerative medial
meniscus injury and unresponsive to the appropriate
conservative treatment. Surgeons performed a detailed
examination of the knee, documenting the range of
motion, the presence of an effusion and the results of
the meniscal and stability tests. The meniscus injury had
to be symptomatic ( joint line tenderness, pain in forced
ﬂexion or a positive McMurray test). Patients with clin-
ical (American College of Rheumatology) criteria47 or
radiographic knee OA were excluded. Radiographic
exclusion criteria included knee OA (grade 2–4) accord-
ing to the Kellgren and Lawrence scale48 depicting def-
inite joint space narrowing or deﬁnite osteophytes.
Other exclusion criteria were a history of obvious trau-
matic onset of the symptoms (symptoms resulting from
kneeling, twisting or slipping without an actual fall were
not considered ‘traumatic’ despite a possible sudden
onset), recent episodes of locked knee (the knee cannot
be fully extended), previous surgical treatment of the
knee, instability or restricted range of motion, previous
(within 1 year) fracture of the index extremity and ﬁnd-
ings on MRI or arthroscopy of any other pathology than
a degenerative meniscus injury (requiring an interven-
tion other than APM; the ﬁnal assessment of chondral
lesions was carried out arthroscopically and, if deemed
osteoarthritic, they were left untreated). Patients unable
to provide informed consent were also excluded. All
inclusion and exclusion criteria are listed in box 2.
Baseline
Baseline assessment included sex, birth date, height and
weight, mechanism of injury (onset of symptoms), time
from the onset of symptoms and standard clinical exam-
ination. After being deemed eligible for inclusion, a
standardised conservative treatment protocol (exercise
programme) was administered by a physiotherapist to all
patients who were also given written instructions to
ensure the adequacy of conservative treatment before
the operation.
Radiographic and MRI
Weight-bearing posteroanterior knee radiography with
the use of a ﬁxed-ﬂexion protocol (knees in 20° of
ﬂexion and the beam oriented 10° above the horizontal
axis)49 50 and a whole leg radiograph for assessing the
possible malalignment was performed for all individuals.
MRI scans were obtained with the use of a 1–3-Tesla
scanner with a phase-array knee coil. An increased
meniscal signal communicating with the inferior, super-
ior or free edge of the meniscal surface seen on two
consecutive slices was considered indicative of a meniscal
injury.51 The x-rays and MRI were assessed by both a
musculoskeletal radiologist and an orthopaedic surgeon
and the ﬁnal grading was carried out by consensus.
After the baseline visit, the eligible patients were
placed on a waiting list for surgery to be operated on
within the subsequent 3 months. If the symptoms sub-
sided between the baseline assessment and the day of
surgery, the patient was excluded from the trial. These
patients, along with those who met the eligibility criteria
but declined to participate in the RCT, were asked to
give permission for follow-up with a protocol identical to
the RCT participants.
Interventions
Arthroscopic examination of the knee was ﬁrst per-
formed for all patients using standard anterolateral and
anteromedial portals with a 4 mm arthroscope (under
spinal or general anaesthesia (one site) according to the
normal practice of the respective hospitals). The ortho-
paedic surgeon evaluated the medial, lateral and patello-
femoral joint compartments and graded the articular
lesions according to the ICRS52 classiﬁcation and the
meniscus injury(-ies) according to the classiﬁcation by
Cooper et al.53 Patients with obvious chondral ﬂaps or
other chondral injuries indicative of trauma, loose
Box 2 Inclusion and exclusion criteria used in the rando-
mised controlled trial
Inclusion criteria
1. Age: 35–65 years of age
2. Persistent (>3 months) pain on the medial joint line of the
knee
3. Pain provoked by palpation or compression of the joint line
or a positive McMurray sign
4. MRI showing signals characteristic of medial meniscus injury
5. Degenerative injury to the medial meniscus confirmed at
arthroscopy
Exclusion criteria
1. Trauma-induced onset of symptoms
2. Locked knee (that cannot be straightened normally)
3. Previous surgical procedure on the affected knee
4. Clinical osteoarthritis (OA) of the knee (American College of
Rheumatology criteria)47
5. Radiological OA of the knee (Kellgren-Lawrence grade >1)48
6. Acute (within the previous year) fracture of the affected
extremity
7. Decreased range of motion of the knee
8. Instability of the knee
9. MRI assessment shows pathology other than degenerative
knee disease requiring treatment other than arthroscopic
partial meniscectomy (APM)
10. Arthroscopic examination reveals pathology other than a
degenerative injury to the medial meniscus requiring inter-
vention other than APM
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bodies or any ﬁnding other than a degenerative medial
meniscus injury (requiring an arthroscopic procedure)
were excluded from the trial. After a thorough arthro-
scopic examination of the knee (conﬁrming the eligibil-
ity of the patient for the RCT), the patients were
randomly assigned to receive APM or placebo surgery.
To ensure the blinding of the patients at the four study
sites using spinal anaesthesia, the blinding of the patient
was further ensured by shielding the patients’ view with
a vertical drape and aiming the arthroscopy monitors
away from the patient’s line of vision.
Randomisation and concealment
To enter a patient into the study, a research/staff nurse
opened an envelope containing the treatment assign-
ment and revealed it to the surgeon by showing the
paper, but the allocation was not expressed verbally. The
sequentially numbered, opaque, sealed envelopes were
prepared by a statistician with no clinical involvement in
the execution of the trial using a computer-generated
schedule and the envelopes were kept in a secure,
agreed location at each centre. To minimise the risk of
predicting the treatment assignment of the next eligible
patient (to ensure concealment), randomisation was
performed in unﬁxed blocks (block size known only to
the statistician). A randomisation sequence of fourfold
stratiﬁcation, including the study site, the age (35–50 or
51–65 years of age), the gender (female or male) and
the existence of radiographic knee OA (no (=K/L 0) or
minor degenerative changes (=K/L 1))48 was used.
Arthroscopic partial meniscectomy
The damaged and loose part of the meniscus tissue was
removed with arthroscopic instruments (mechanised
shaver and meniscal punches) until solid meniscus tissue
was reached. The meniscus was then propped to ensure
that all loose and weak fragments and unstable meniscus
tissue had been successfully resected, preserving as
much of the meniscus tissue as possible.54 No other sur-
gical procedure (synovectomy, debridement, excision of
fragments of articular cartilage or chondral ﬂaps, or
abrasion and/or microfracture of chondral defects) was
performed.
Placebo surgery
A standard APM procedure was simulated. The surgeon
asked for all instruments and manipulated the knee as if
APM was being performed. The mechanised shaver
(without the blade) was also pushed ﬁrmly against the
patella, outside of the knee, to mimic as closely as pos-
sible the feelings and sounds of the normal use of the
arthroscopic shaver. Further, to simulate the sounds of
normal APM, suction was also used to drain the joint
and saline was splashed. The patient was kept in the
operating room for the amount of time required to
perform an actual APM.
All procedures were standardised across sites.
Furthermore, all arthroscopies were video-recorded for
later analysis and to ensure the comparability of all
interventions.
In both APM and placebo surgery groups, the post-
operative care was delivered according to a standard
protocol specifying that all patients received the same
walking aids and graduated exercise programme.
Analgesia was given according to standard practice. All
patients were discharged after full postoperative recov-
ery. The staff delivering the care was blind to the treat-
ment allocation. The notes specifying the actual
procedure (APM or placebo) were sealed inside an enve-
lope, but the arthroscopic ﬁndings and a phrase ‘a pro-
cedure according to the degenerative meniscus trial was
performed’ were included in the patients’ medical
records.
Prospective cohort (for the ‘RCT within-a-cohort’ design)
Additionally, in one of the ﬁve study centres (the initial
site in which over half of the participating patients were
enrolled), all patients scheduled for a knee arthroscopy
were followed up prospectively with a follow-up assess-
ment protocol identical to that in the actual trial. Those
with a degenerative meniscus injury (but who had
somehow bypassed our recruitment, were treated by an
orthopaedic surgeon not participating in the trial or
were excluded from the trial) form a non-randomised,
pragmatic, prospective cohort. This pragmatic cohort,
together with the patients treated in the actual RCT
(those randomised and also those who declined to be
randomised), constitutes the ‘RCT within-a-cohort’ study
population (ﬁgure 2A).
Outcome measures
The symptoms currently believed to be attributable to a
torn meniscus are mostly subjective (pain, discomfort
and possible functional deﬁcits) and ﬂuctuating in
nature, and accordingly our outcomes are patient-
administered outcome measures. The follow-up scheme
of this trial consists of four questionnaires (one
condition-speciﬁc outcome measure, one pain measure,
one disease-speciﬁc quality of life index and one generic
health-related quality of life (HRQoL) index), which are
administered preoperatively (on the day of surgery), and
then again at 2, 6 and 12 months postoperatively.
Postoperative questionnaires were/are mailed to the
patients with an enclosed prepaid return envelope. In
case of non-response, the study coordinator contacts
these participants by phone, requesting the return of
the follow-up questionnaire. At the 12-month follow-up
point, the patients are also asked to respond to the fol-
lowing questions: (1) which procedure (APM or placebo
surgery) do they think they have undergone, (2) is the
knee better than before the intervention, (3) are they
satisﬁed with their knee at present and (4) would they
choose to be operated on again if they had to make the
decision now. A ﬂowchart of the follow-up scheme is pre-
sented in ﬁgure 3.
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Lysholm knee score
The Lysholm knee score was originally designed to
evaluate knee function and symptoms in activities of
daily living in patients with anterior cruciate ligament
insufﬁciency.55 It has later been adjusted and validated
for the evaluation of meniscal injuries.56 57 The Lysholm
knee score is a condition-speciﬁc outcome measure with
eight domains: limp, locking, pain, stair climbing, use of
supports, instability, swelling and squatting.58 An overall
score of 0–100 points is calculated, 0 denoting the worst
possible outcome and 100 the opposite.58
Numerical rating scale for pain
Knee pain at rest and after exercise (over the last week)
will be assessed on a 0–10 numerical rating scale, (NRS)
comprising ‘no pain’ at the left (0) and ‘extreme pain’
at the right (10). NRS is easy to administer and has
been validated as a measure of pain intensity in popula-
tions with known pain.59
Western Ontario Meniscal Evaluation Tool
The Western Ontario Meniscal Evaluation Tool
(WOMET) is a disease-speciﬁc tool designed to evaluate
HRQoL in patients with meniscal pathology.60 It has
been developed to be the measure including the most
important items for patients with meniscal tear61 and
was recently validated for patients with degenerative
meniscus injury.62 WOMET contains 16 items addressing
three domains: nine items for domains of physical symp-
toms, four for domains of disabilities due to sports,
Figure 2 (A) The diagram illustrates the randomised controlled trial (RCT) within-a-cohort study design. By prospectively
following up all patients undergoing arthroscopic surgery for their degenerative meniscus injury (and not just those randomised to
the efficacy RCT), we are able to obtain several distinct groups of patients with distinct prognostic factors. These groups will enable
us to address several interesting hypotheses regarding the efficacy, effectiveness and cost-effectiveness of arthroscopic partial
meniscectomy (APM). (B) A theoretical scheme based on Cochrane’s three-step hierarchy of evidence for addressing the efficacy,
effectiveness and cost-effectiveness of APM. By comparing the treatment response of groups C and D, we can address the
efficacy of APM: Is the APM superior to placebo? Then, to elucidate whether our RCT truly represents a ‘best-case scenario’ (a true
efficacy trial), we will assess whether the outcome of group E is superior to any subgroup of patients within the pragmatic cohort
(B). If these hypotheses hold true, we can continue to ‘the second ladder of evidence’, effectiveness. We feel that the treatment
response observed in the pragmatic cohort (B) should be clearly more robust than the placebo effect of APM to claim that evidence
of effectiveness exists. The placebo effect of APM, in turn, can be ‘extracted’ by subtracting the difference between the groups
D and C (blinded APM minus blinded placebo) from the outcome of group E (open APM), a group that should entail the combined
effects of placebo and APM. Finally, if evidence of effectiveness is obtained, we can proceed to the assessment of the possible
cost-effectiveness (‘cost-efficacy’—extrapolation) of APM.
Figure 3 A diagram outlining the follow-up scheme used in the efficacy randomised controlled trial.
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recreation, work and lifestyle and three for the emotions
domain.60 Each of the WOMET items is given a visual
analogue scale (100 mm lines anchored at the ends).
The best or least symptomatic situation ranks 0 and the
most symptomatic rank possible is 1600.60 For the sake
of simplicity, the score is usually converted to a percent-
age of normal, in which zero (0) denotes the worst pos-
sible situation and 100 the best possible situation.
15D
The 15D instrument is a generic HRQoL instrument com-
prising 15 dimensions.63 For each dimension, the respond-
ent must choose one of the ﬁve levels that best describes
his/her state of health at the moment (the best level being
1 and the worst level being 5). A set of utility or preference
weights is used in an addition aggregate formula to gener-
ate a single index number, the utility or 15D score. The
maximum 15D score is 1 (no problems on any dimension)
and the minimum score is 0 (being dead). The responsive-
ness, reliability and validity of 15D have been thoroughly
established, and this instrument has been used extensively
in clinical and healthcare research.64 65
Initially, our two primary outcome measures were the
Lysholm knee score55 and the NRS for pain (VAS) at
12 months after surgery. The secondary outcome was the
WOMET60 score at the same time point and a cost-utility
analysis (based on the patients’ general quality of life
using the 15D score and the utilisation of healthcare
resources). At this preregistration stage (2007), the
Lysholm score was conceived of as a prespeciﬁed
primary outcome as this tool has been validated for
meniscus injury56 and is also the outcome instrument
used most often for various knee conditions.58 66
However, during the recruitment phase of the trial, we
showed that WOMET has acceptable psychometric prop-
erties for the evaluation of patients with a degenerative
meniscus injury and early OA,62 and accordingly have
now decided to use it as our third primary outcome.
Reoperations/treatment conversions
Patients were told at the time of giving their consent
that they would be allowed to consider crossing over to
the other procedure 6 months or later after the arthro-
scopic procedure if adequate relief of symptoms was not
achieved (based on the existing evidence showing that it
can take up to 6 months postoperatively to obtain the
actual beneﬁt from the APM).67 68 No speciﬁc numer-
ical thresholds of outcome measures were set for the
option for crossover, but the patients will be asked in the
6-month follow-up questionnaire about their willingness
to undergo reoperation based on their current symp-
toms. If a patient reports symptoms requiring attention
at 6-month follow-up or becomes symptomatic after that,
an appointment will be scheduled with an orthopaedic
surgeon both blind to the initial treatment and not
involved in the care of the patient before the appoint-
ment. If the clinical examination carried out at this
point reveals clinical signs indicative of/consistent with a
meniscal tear and the patient requests reoperation, the
allocation will be unsealed and the patient will be
offered APM. The number of patients both requiring
additional follow-up appointments and unsealing of the
allocation is registered in both the APM and placebo
groups. MRI is not automatically performed for symp-
tomatic patients because of its low speciﬁcity in differen-
tiating residual or recurrent symptoms from the signal
due to postresection (APM).69 However, in case of a new
trauma to the index knee or exceptionally severe symp-
toms, an MRI examination will also be carried out. In
addition to the aforementioned predetermined assess-
ment of the possible adverse events in the 6-month
follow-up questionnaire, the patients are instructed to
contact the study coordinator with any possible com-
plaints related to the knee surgery at any given moment
during the postoperative period. These contacts (events)
will be registered.
Loss to follow-up
As in an earlier placebo surgery controlled trial,70 we
will document the number and proportion of indivi-
duals eligible for and compliant with each follow-up.
Individuals who die during the study (from causes unre-
lated to the study or procedure) will also be tabulated. If
the proportion of individuals withdrawing from either
arm is greater than the anticipated 20% at 1 year, an
analysis of the demographic and prognostic characteris-
tics will be made between the individuals who withdraw
and those who remain in the study. For continuous vari-
ables, parametric or non-parametric analysis of variance
will be used. For categorical variables, χ2 or Fisher’s
exact test will be applied.
Missing items
When individual items are missing from a scale, we will
calculate the per cent of missing items.
If the missing items are less than 10%, we will impute
values using the mean of the remaining items. If more
than 10% of the scale score is unavailable for analysis,
the patient will be excluded from the analysis at that
time point. For the WOMET score, our approach to
missing values is slightly different: If a patient fails to
complete 1–3 items, we will substitute the missing value
(s) with the average value for the answered items accord-
ing to the protocol described previously for the Western
Ontario and McMaster Universities Osteoarthritis Index,
a similar outcome tool used for the assessment of estab-
lished knee OA.71 72
Sample size
For the sample size calculation, we used our prospect-
ively collected database of 377 consecutive patients with
a degenerative meniscus injury who had undergone
APM (data not published). Minimal clinically important
improvement (MCII) was assessed with an anchor-based
method (patient’s global impression of change used as
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an external anchor).73 MCII was found to be 11.5 for
the Lysholm knee score and 15.5 for the WOMET score.
SDs for the response (postoperative score—preoperative
score) of the same population were 21.1 and 24.5 for
the Lysholm and WOMET scores, respectively. For the
determination of the MCII for pain, we extrapolated our
estimates from the existing literature on pain-VAS.
Patients with knee OA report the MCII for pain to be
19.9 mm74 and in our own cohort, the SD of response of
pain after exercise was 31.4 mm. Using these estimates,
the required sample sizes were 40, 54 and 40 partici-
pants per group for the Lysholm score, WOMET score
and pain assessment, respectively, with 80% power to
show a clinically meaningful advantage of APM over
placebo, based on a two-sided type 1 error rate of 5%.
Given an anticipated dropout level of 20% and the pos-
sible problems related to uneven randomisation (multi-
centre design with sites as one stratum), we decided to
recruit 70 patients per group.
Safety analysis
For obvious ethical and safety reasons, an interim ana-
lysis by an independent data and safety monitoring
board (the National Institute for Health and Welfare)
was carried out after the enrolment of 70 (50%) patients
to ensure that the rates of complications or rearthrosco-
pies were within acceptable limits (within the normal
rate of complications and/or reoperations related to
knee arthroscopy). This analysis is planned to be carried
out blind to the group assignment and unless a marked
discrepancy is found in the incidence of complications/
reoperations, the allocation concealment will be pre-
served. No other interim analysis is envisaged.
Data management
At each study site, the data are collected by a research
nurse dedicated to the study. Forms are mailed to the
coordinating centre (Hatanpää Hospital, Tampere),
where all data are entered into a computerised database.
After the completion of follow-up, all data are re-entered
by an individual with no clinical involvement in the exe-
cution of the trial and then these two separate databases
are compared for consistency. Participant ﬁles will be
maintained in storage (both in electronic and paper
format) at the coordinating centre for a period of
5 years after completion of the study.
Blinded data analysis
The Steering and Writing Committees (RS, MP, AM and
TLNJ) will develop and record two interpretations of
the results on the basis of a blinded review of the
primary outcome data (treatment A compared with treat-
ment B), with one assuming that A is the APM group
and another assuming that A is the placebo surgery
group. The Writing Committee will also deliberate
before data analysis to determine the key analyses and
presentation format for the primary publication. The
minutes of this meeting are recorded as a statement of
interpretation document, which will be signed by all
members of the Steering and Writing Committees
before the unsealing of the randomisation.75
Statistical methods
The trial was designed to ascertain the superiority of
APM over placebo at 12 months with primary outcome
measures by the means of statistically signiﬁcant differ-
ences between the groups. Baseline characteristics will
be analysed by descriptive statistics. For the primary ana-
lysis, the change in scores (Lysholm and WOMET) and
pain (NRS) at 12 months will be compared between the
two study groups. A secondary analysis of the primary
endpoint will adjust for those prerandomisation vari-
ables which might reasonably be expected to inﬂuence
the outcome (ie, sex, age, radiological OA and baseline
score). A two-sided p value of 0.05 will be considered to
indicate statistical signiﬁcance. We will use the
Bonferroni method to appropriately adjust the overall
level of signiﬁcance for multiple (three) primary out-
comes. Analyses of the outcome measures score will also
be performed at 2 and 6 months. Additionally, the
number and percentage of satisﬁed patients, those sub-
jectively improved, and those whose allocation was
unsealed will be calculated and compared between the
two groups. All statistical analyses will be performed on
an intention-to-treat basis, meaning that data from
patients will be analysed according to the initial study-
group assignment regardless of compliance with ran-
domisation. However, as the potential for treatment con-
version exists, but only from placebo surgery to APM,
per-protocol analysis will also be carried out. We plan to
conduct a subgroup analysis to compare the result based
on the degree of radiographic OA (K&L 0 vs I). The
serious adverse event rates occurring within 12 months
of surgery for both study arms will be evaluated descrip-
tively in aggregate and separately. If the number of
events is large enough to allow more sophisticated ana-
lysis, the rates between the APM and placebo arms will
be compared. The data will be presented by the total
number of events and the total number of individuals
with at least one event.70
IBM SPSS Statistics (V.20 or later, IBM Corporation) is
used for all statistical analyses.
ETHICS AND DISSEMINATION
Ethical issues related to the use of placebo surgery
Our application to the Pirkanmaa Hospital District IRB
contained a speciﬁc, six-point ethical analysis focusing
on the methodological rationale for use of placebo
surgery, risk-beneﬁt assessment and informed consent as
outlined by Miller (box 1).31
Dissemination
The ﬁndings of this study will be disseminated widely
through peer-reviewed publications and conference
presentations.
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DISCUSSION
In this protocol paper, we describe the execution of a
randomised, placebo surgery controlled trial for the
assessment of the efﬁcacy of APM in patients with a
degenerative meniscus injury. Given the imminent risk
for bias from an unblended trial of surgery versus
medical (conservative) treatment—particularly acknow-
ledging the potential of surgery to produce powerful
placebo effects32 76 77—it is doubtful that a rigorous trial
of surgery can be conducted without a sham surgery
control when the primary outcome is pain, patient-
reported improvement or quality of life.24 78 79 As the
only previous placebo surgery controlled trial in knee
arthroscopy32 prompted signiﬁcant criticism from the
orthopaedic discipline at large,15 80–91 we decided to use
this debate as a template in rationalising our methodo-
logical choices (table 1).
GENERALISABILITY
Alleged poor generalisability was the most prevalent
concern regarding the study by Moseley et al.15 80–83 85 87–91
Explanatory trials are designed to measure the efﬁcacy of
an intervention—to ﬁnd out if the treatment exerts a bio-
logical effect in a research setting under ideal and controlled
conditions. The factors most consistently found to predict
a poor outcome after APM in patients with a degenerative
meniscus injury are advanced knee OA and chondral
damage.39 94 95 Also, lateral meniscectomy has been iden-
tiﬁed as a predictor of poorer prognosis rather than
medial meniscectomy.39 96 Accordingly, to obtain a popu-
lation with ‘best-possible response to APM’, we chose to
recruit patients with a stable knee, no or minimal OA and
an isolated, degenerative injury of the medial meniscus.
Although age per se is not a predictor for poor outcome,
it has been shown to be associated with increased
Table 1 Concerns expressed regarding the Moseley et al32 trial and their related pilot study92 and our solution to these
concerns




▸ Lack of well-defined exclusion criteria
▸ Suboptimal study population
– Stage of OA
– Mechanical symptoms
– Meniscal tears













Study population represents ‘best-case scenario’
RCT within-a-cohort design (pragmatic cohort
included)
Number of denial (selection bias) Chambers (2002)83 Study population represents ‘best-case scenario’
Only one surgeons Kirkley (2008)15
Felson (2010)91
Multicentre study, five experienced knee
surgeons





No intention-to-treat analysis Felson (2002)80 Intention-to-treat analysis
Power calculations not based on primary
outcome
Chambers (2002)83 Prior power calculations based on primary
outcomes
Post hoc equivalency bounds Chambers (2002)83
Gillespie (2003)87
Superiority trial design, but equivalency
trial conclusions




Insufficient socioeconomic data Johnson (2002)85
Insufficient data on anatomy and surgical
procedures performed
Johnson (2002)85 Standardised data collecting form and video
recordings of all surgical procedures
Data reported as group average Chambers (2002)83 Possibility to report the results as proportion of
those who benefited/satisfied
Investigator bias Ilahi (2010)90
Concerns regarding possible existence
of placebo effect
Hartman (1997)93 RCT within-a-cohort design
OA, osteoarthritis; RCT, randomised controlled trial.
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prevalence of OA and (consequently) inferior functional
recovery after APM.39 Similarly, women have also been
found to have a less favourable prognosis after APM.94
These two factors were thus used as stratiﬁcations.
Acknowledging the obvious risk of high internal but
low external validity due to the strict eligibility criteria,
we decided to also keep track of the patients eliminated
from the RCT by prospectively following these indivi-
duals with the same outcome assessment arsenal used in
the RCT. One of the reasons for collecting this prag-
matic cohort was to safeguard against bias attributable to
patients declining to take part in a placebo surgery con-
trolled trial. However, unlike in the trial by Moseley
et al32 (only about 40% of the eligible patients agreed to
participate), we have been very successful in convincing
patients to participate (15% of eligible patients
declined). This pragmatic cohort will also be used to
corroborate or refute whether our efﬁcacy (RCT) popu-
lation represents the best-case scenario (those with
optimal response to APM) (ﬁgure 2B).
SINGLE VERSUS MULTIPLE SURGEONS/CENTRES
The study by Moseley et al32 has also been criticised for
having only one surgeon performing all operations.15 32 91
Similar to Moseley et al,32 we also began our trial in only
one centre/surgeon, but once the study protocol had
been thoroughly reﬁned, it was expanded to four add-
itional sites. The inclusion of ﬁve surgeons/study sites
entails one problem: we chose to use ‘study site’ as our
fourth stratiﬁcation (separate randomisation sequences
for each site), and accordingly, there is an imminent risk
of uneven randomisation as the number of patients allo-
cated at each of the four additional sites is relatively
small (projected to be 10–20/site) and there are three
stratiﬁcations in the randomisation. However, the use of
separate randomisation sequences was a conscious
choice, as we wanted to retain the possibility of analysing
the data separately from each site.
RANDOMISATION
By postponing the randomisation into the operation
suite, we have managed to completely eliminate the
chance that any eligible patient who gives informed
consent would decline to participate in the trial after
being randomised. Even though our ‘RCT
within-a-cohort’ design allows us to also follow up those
declining, the elimination of postrandomisation declin-
ing obviously decreases the risk of bias.
OUTCOME ASSESSMENT AND STATISTICAL ANALYSIS
According to the CONSORT statement,97 authors
should not only deﬁne the prespeciﬁed outcome consid-
ered to be of the greatest importance to relevant stake-
holders, but they should also indicate the prespeciﬁed
time point of primary interest when outcomes are
assessed at several time points after randomisation. Few
would argue that the goal of treatment in patients with
degenerative meniscus injury is anything but to relieve
symptoms, particularly as the existing evidence quite
convincingly shows that degenerative meniscus injury
per se and APM both inevitably lead to the development
of knee OA.36–38 As noted previously, it can take up to 6
months postoperatively to obtain the full beneﬁt from
the APM,67 68 but a more lasting relief of symptoms
seems to be confounded by eventual progression of the
underlying degenerative process. Accordingly, to be able
to showcase the potential efﬁcacy of APM on pain and
the quality of life while minimising various types of con-
founding (eg, non-retention/loss to follow-up and pro-
gression of knee OA), we chose a 12-month time point
as our time point of primary interest. However, the
potential beneﬁcial or detrimental short-term effects of
either of the studied procedures (eg, possible transient
accelerated recovery) can also be assessed using the data
from the 2-month and 6-month follow-up assessments.
Further, as Moseley et al32 were also criticised for report-
ing only average change of a group,86 we decided to ask
our patients about their global impression of change
with their knee status and their satisfaction with their
knee. These two questions enable us to also report the
outcome of our population as a proportion of patients
who consider they have beneﬁted from the treatment.
As for the prespeciﬁed outcome of the greatest
importance to patients, Moseley et al32 developed a
patient-administered outcome instrument of their own,
a methodological choice that was criticised as the tool
was not properly validated.15 80 83 86 We have chosen
three validated outcome instruments in our trial. To
safeguard against potential problems associated with
multiplicity of analyses,97 our solution is twofold. We will
use the Bonferroni method to appropriately adjust the
overall level of signiﬁcance and also take this issue into
account in interpreting our ﬁndings: to be deemed
hypothesis-proving, the intervention-induced changes
have to be well aligned and clinically meaningful in all
three validated primary outcomes.
LIMITATIONS OF THE STUDY
The deﬁnition of the concept ‘degenerative’ or ‘trau-
matic’ in the context of meniscal injuries is arbitrary in
nature. Traditionally, meniscal injuries or tears have been
classiﬁed as traumatic or degenerative based on the aeti-
ology (injury mechanism) or morphology (tear pattern
observed in MRI or at arthroscopy), but no validated and
generally agreed criteria exist to make the distinction
between the two entities. Even the deﬁnition of the word
‘trauma’ represents a challenge. Although a ‘traumatic’
onset of symptoms is indeed an exclusion criterion in our
RCT, the majority of patients with a ‘degenerative’ menis-
cus injury do experience some kind of twisting movement
or other relatively modest injury prior to the onset of
their knee symptoms.98 Accordingly, all patients with
sudden injuries related to their own voluntary muscle
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activities (such as kneeling, bending or kicking) and
patients with a minor twisting of the knee were included
in our trial. In essence, our criteria labelling a tear as
‘traumatic’ describe a more substantial event, such as
falling from a chair, stairs or bicycle or slipping on ice. To
increase the validity of the classiﬁcation of the meniscus
injury, our assessment includes not only history/clinical
examination but also MRI and arthroscopy. Finally, our
RCTwithin-a-cohort design allows us to examine whether
the response to APM of those excluded from the RCT
because of ‘traumatic’ meniscal injury differs from those
included in the RCT.
A similarly controversial issue is the differentiation of
chondral injuries that require surgical procedure
(debridement, microfracture or any other procedure)
from those that should be considered merely osteoarth-
ritic.99 To the best of our knowledge, there is no object-
ive classiﬁcation system (either MRI or arthroscopy
based) for this distinction. Our rationale was to use pre-
operative MRI to verify that the patients’ symptoms
could be due to degenerative meniscus injury (and to
exclude possibly rare situations as knee tumours). No
cartilage lesions detected in MRI were considered an
exclusion, but the ﬁnal decision whether or not to
include the patient in the trial was made at arthroscopy,
where the meniscus injury (and commonly associated
chondral lesions) were visually and physically (probing)
veriﬁed and assessed. As there really is no valid (RCT
-based) evidence to show that surgery would provide any
clinically meaningful improvement in patients with
degenerative chondral lesions,15 32 we instructed our sur-
geons to generally forbear from surgical intervention.
However, if a single large chondral ﬂap or local deep
osteochondral lesion was found, the surgeons were given
permission to carry out the surgical procedure they
deemed appropriate and the patient was excluded.
Finally, the only difference between our two allocation
groups is whether a meniscus resection was carried out
or not. Accordingly, if we made a wrong decision con-
cerning chondral lesions, they should still be evenly
divided into the two study arms, thus not compromising
our primary objective.
INTERPRETATION OF THE RESULTS: INTRODUCING
VARIOUS POTENTIAL SCENARIOS
To illustrate the various potential ﬁndings of the study, we
have ﬁtted different scenarios within a larger context of
Cochrane’s three-step hierarchy of evidence (ﬁgure 2B).
This scheme outlines the requirements for evidence to
justify claims of proven efﬁcacy, effectiveness and, ultim-
ately, the cost-effectiveness of APM.
Quantifying the placebo effect
The placebo effect refers to a positive change in symp-
toms related to a participant’s perceptions of the treat-
ment rather than to the mechanisms of the treatment
itself.21 After the publication of their pilot study,92
Moseley et al were questioned about the possibility that
patients who enrolled in their placebo surgery con-
trolled study would be more ‘suggestible’ and therefore
more susceptible to the placebo effect.93 Moseley
responded by proposing two alternative scenarios: either
the patients in their RCT would be more susceptible to
the placebo effect than the patients who declined to be
in the study (suggesting that the characteristics and per-
sonality traits of patients who choose to enrol in the
studies are different from those declining) or patients
who enrol in the RCT are more susceptible to the
placebo effect than patients who undergo surgery
outside a study. For the sake of brevity, we will not enter
into a lengthy elaboration of these two alternative inter-
pretations (which can be found in the detailed response
by Moseley100).
Translating this line of thought into our study design,
potential differences in the responses to treatment
between the RCT study groups (C, D and E, ﬁgure 2A)
are attributable to either the effect of resection (groups
C vs D, ﬁgure 2A) or the magnitude of the placebo
effect (groups C vs E, ﬁgure 2A). What makes our
design unique is the opportunity to actually disentangle
(quantify) the respective effects of ‘resection’ and
‘placebo’. Further, by comparing (with appropriate base-
line adjustment) these estimates with the treatment
responses observed in the patients who have undergone
APM outside our study (group B, ﬁgure 2A) and the
more heterogeneous pragmatic cohort (group A,
ﬁgure 2A), we should also be able to extrapolate the
potential effectiveness of the procedure (ﬁgure 2B).
Theoretically, the placebo effect is more robust in the
‘open label’ (E) and pragmatic groups (A and B) than
in the efﬁcacy trial groups (C and D) due to the doubt
inherent in any ‘blinded’ RCT (ﬁgure 2A). To summar-
ise, there is a placebo effect in all ﬁve study groups, not
just the placebo surgery group (D).
CONCLUSION
In this article, we present a protocol for a randomised
placebo surgery controlled trial to assess the efﬁcacy of
APM in patients with degenerative meniscus tear. We
have also discussed some of the methodological issues
that we feel are most pertinent to the successful execu-
tion of a controlled surgical trial, particularly with
respect to minimising bias and maximising the internal
and external validity of the study.
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